

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
BEFORE THE BOARD OF PATENT APPEALS AND INTERFERENCES

In re application of:

Sherri M. BROWN *et al.*

Appln. No.: 09/955,216

Filed: September 19, 2001

For: **Nucleic Acid Molecules and Other Molecules Associated with the Gibberellin Pathway**

Confirmation No.: 1690

Art Unit: 1634

Examiner: Sarae L. Bausch

Atty. Docket: 16517.257

**APPELLANT'S BRIEF**

**Mail Stop Appeal Brief – Patents**

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

Sir:

This is an Appeal from the Final Rejection of all claims pending in the above-captioned patent application. A Notice of Appeal was filed on August 5, 2004. Authorization to charge the official fees for this filing is given in the accompanying transmittal letter.

**1. Real Party in Interest**

The real party in interest is Monsanto Company, a Delaware corporation with offices at 800 North Lindbergh Boulevard, St. Louis, Missouri 63167.

**2. Related Appeals and Interferences**

Appellant identifies the following judicial proceeding, which may have a bearing on the Board's decision in the present Appeal. On May 27, 2004, the Real Party in Interest in the above-captioned matter filed an appeal to the United States Court of Appeals for

the Federal Circuit (“Federal Circuit”) from a decision by the Board in *In re Fisher*. (U.S. Appln No. 09/619,643, B.P.A.I. Appeal No. 2002-2046, Fed. Cir. Case No. 04-1465). The Federal Circuit’s decision in *In re Fisher* may have a bearing on the Board’s decision with regard to at least one of the grounds of rejection in the present appeal. A copy of the Board’s decision in Appeal No. 2002-2046 is attached hereto as Appendix C.

### **3. Status of Claims**

Claims 10 and 20-25 are pending. Claims 1-9 and 11-19 were cancelled without prejudice to or disclaimer of the subject matter claimed therein in a preliminary amendment filed September 19, 2001 and in an amendment filed December 9, 2003. Claims 22 and 23 were cancelled without prejudice to or disclaimer of the underlying subject matter in an after final amendment filed concurrently herewith. Claims 10 and 20-25 stand finally rejected under 35 U.S.C. §§ 101 and 112, first paragraph, claims 22-25 stand finally rejected under 35 U.S.C. § 112, second paragraph, and claims 20-25 stand finally rejected under 35 U.S.C. § 102(b). Appellant appeals all of the rejections of claims 10 and 20-21 and 24-25.

### **4. Status of Amendments**

Subsequent to the Final Office Action mailed May 5, 2004 (“Final Action”) in this case, an Amendment After Final Rejection (the “Amendment”) was filed on July 6, 2004 amending claims 20 and 25. In response to the Amendment, an Advisory Action was subsequently mailed by the U.S. Patent and Trademark Office on July 13, 2004 (“Advisory Action”), stating that “[f]or purposes of Appeal, the proposed amendment(s) will be entered....”

Appellants have filed a Second Amendment after Final Rejection concurrently herewith canceling claims 22 and 23. The amendment is intended to clarify the issues on appeal.

## **5. Summary of Claimed Subject Matter**

The claimed subject matter is directed to an isolated nucleic acid molecule comprising the nucleic acid sequence of SEQ ID NO: 7 or its complement. Specification at page 40, lines 5-19. The claimed subject matter is also directed to a substantially purified first nucleic acid molecule that encodes a maize copalyl diphosphate synthase enzyme or fragment thereof, where the first nucleic acid molecule comprises a nucleic acid sequence that hybridizes under conditions of 6.0 X sodium chloride/sodium citrate (SSC) at about 45°C, followed by a wash of 2.0 X SSC at 50°C to a second nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 7 or its complement. Specification at page 16, lines 10-14 and page 38, line 13 through page 40, line 4. The claimed subject matter is also directed to a substantially purified nucleic acid molecule, where the nucleic acid molecule comprises a nucleic acid sequence that shares between 100% and 98% sequence identity with SEQ ID NO: 7 or its complement. Specification at page 40, lines 5-19.

## **6. Grounds of Rejection to be Reviewed on Appeal**

The grounds of rejection to be reviewed in this Appeal are:

(a) pending claims 10 and 20-25 stand rejected under 35 U.S.C. § 101 for allegedly being unsupported by a specific asserted utility or a well established utility;

(b) pending claims 10 and 20-25 stand rejected under 35 U.S.C. § 112, first paragraph, for alleged lack of enablement because the claimed invention purportedly lacks utility;

(c) pending claims 20-25 stand rejected under 35 U.S.C. § 112, first paragraph, for alleged failure to comply with the enablement requirement;

(d) pending claims 10 and 20-25 stand rejected under 35 U.S.C. § 112, first paragraph, for alleged insufficiency of written description;

(e) pending claims 22-25 stand rejected under 35 U.S.C. § 112, second paragraph, for alleged failure to particularly point out and distinctly claim the subject matter; and

(f) pending claims 20-25 stand rejected under 35 U.S.C. § 102(b) for alleged anticipation.

#### **A. Grouping of Claims**

Claims 10 and 20-25 remain in this case. Claims 10, 20 and amended claim 24 are independent. Claims 22 and 23 have been cancelled in an after final amendment filed concurrently herewith. All of the claims at issue do not stand or fall together and the separate patentability of claims 10, 20 and 24 is particularly addressed in Sections 7.B(1)(d), 7.D(3), and 7.D(4) below. A copy of the claims on appeal is attached hereto as Appendix A, as well as a copy of the amended claim submitted in the Amendment after Final Rejection filed concurrently herewith in Appendix B.

### **7. Argument**

#### **A. Summary of Appellant's Position**

As the Supreme Court said in *Brenner v. Manson*, the “basic *quid pro quo* contemplated by the Constitution and the Congress for granting a patent monopoly is the benefit derived by the public from an invention with substantial utility...where specific benefit exists in currently available form.” 383 U.S. 519, 534-35, 148 U.S.P.Q. 689, 695 (1966). Appellant has met their part of the bargain – they have disclosed nucleic acid molecules which, in their current form, provide at least one specific benefit to the public, for example use to identify the presence or absence of a polymorphism in a population of maize plants. This benefit is specific, not vague or unknown, and it is a “real world” or substantial benefit. Because the claimed nucleic acid molecules provide at least these benefits, they satisfy the utility requirement of 35 U.S.C. § 101. Because the

specification teaches how to make and use the claimed nucleic acid molecules for the disclosed utilities, the enablement requirement of 35 U.S.C. § 112 has been met.

Furthermore, Appellant has provided an adequate description of the claimed nucleic acid molecules that demonstrates Appellant's possession of the claimed invention. The genera of claimed nucleic acid molecules, for example, the genus of nucleic acid molecules comprising the nucleic acid sequence of SEQ ID NO: 7 or its complement have been described by the recitation of common structural features, *e.g.*, the nucleotide sequence of SEQ ID NO: 7, which distinguish molecules in the claimed genera from molecules not in the claimed genera. Because the specification demonstrates that Appellant had possession of (and have provided an adequate description of) the claimed genera of nucleic acid molecules, the specification satisfies the written description requirement of 35 U.S.C. § 112.

The claimed nucleic acid molecules are novel over the prior art. The claims are directed to nucleic acid molecules which encodes a maize copalyl diphosphate synthase or fragment thereof comprising the nucleic acid sequence of SEQ ID NO: 7, as well as nucleic acid sequences comprising SEQ ID NO: 7 and variations thereof. The references cited by the Examiner disclose random primers that are primarily hexanucleotides as well as other copalyl diphosphate synthases. The Examiner has asserted an untenable interpretation of the claims to cover small fragments of the specifically claimed nucleic acid molecule, *i.e.*, molecules as short as two base pairs, and thus concludes that the claim is anticipated by the cited references. However, the currently pending claims, as well as the proposed amended claims, are directed to a nucleic acid molecule which encodes a maize copalyl diphosphate synthase enzyme or fragment thereof, *i.e.*, a fragment of a maize copalyl diphosphate synthase enzyme, wherein the nucleic acid molecule comprises the nucleic acid sequence of SEQ ID NO: 7. Absent a teaching of

each and every element of the claim, *i.e.*, SEQ ID NO: 7, the references cited by the Examiner do not anticipate the present claims.

**B. The Claimed Nucleic Acids Have Legal Utility**

Claims 10 and 20-25 stand rejected under 35 U.S.C. § 101 as allegedly “not supported by a substantial utility.” Final Action mailed May 5, 2004 (“Final Action”), at page 3. Appellant has cancelled claims 22 and 23 in an amendment after final filed concurrently herewith, and will therefore direct their arguments to claims 10, 20-21 and 24-25.

The Examiner acknowledges that the specification asserts that the claimed nucleic acid sequence “encodes a maize copalyl diphosphate synthase enzyme or fragment thereof.” Final Action at page 4. The Examiner further acknowledges that the utilities are based upon “a high percentage sequence similarity” to an experimentally known sequence encoding a kaurene synthase A (copalyl diphosphate synthase). *Id.* However, the Examiner asserts that “[i]t is known for nucleic acids as well as proteins, for example, that even a single nucleotide or amino acid change or mutation can destroy the function of the biomolecule in many instances, albeit not in all cases.” *Id.* The Examiner also asserts that the claimed sequence is not disclosed as a full-length open reading frame and “it is unpredictable if SEQ ID NO: 7 will successfully encode a functional enzyme.” *Id.* The Examiner also asserts that further research would be required to confirm a ‘real world’ use. *Id.*, at page 5.

In addition to encoding a copalyl diphosphate synthase, the specification describes multiple other utilities for the present invention that are independent of the sequence’s ability to encode a copalyl diphosphate synthase enzyme or fragment thereof, including isolating a variety of agronomically significant genes, acquiring molecular markers, promoters, cis-regulatory elements, identifying polymorphisms, and as probes for assisting in the isolation of full-length cDNAs or genes, gene mapping, isolation of

homologous sequences, and the detection of gene expression. *See, e.g.*, specification at page 57, line 3 *et seq.*, under the heading “Uses of the Agents of the Invention.” However, the Examiner asserts these utilities “are non-specific uses that are applicable to nucleic acid(s) in general and not particular or specific to the nucleic acids being claimed.” Final Action at page 9.

This analysis misstates the nature of the asserted uses, ignores disclosed utilities, and misapplies the doctrine of “practical utility” developed by the courts after *Brenner v. Manson*. The “threshold for utility is not high: An invention is ‘useful’ under section 101 if it is capable of providing some identifiable benefit.” *Juicy Whip, Inc. v. Orange Bang, Inc.*, 185 F.3d 1364, 1366, 51 U.S.P.Q.2d 1700, 1702 (Fed. Cir. 1999), *citing Brenner v. Manson*, 383 U.S. 519, 534 (1966). Furthermore, an invention need only provide one identifiable benefit to satisfy 35 U.S.C. § 101. *See Raytheon Co. v. Roper Corp.*, 724 F.2d 951, 958, 220 U.S.P.Q. 592, 598 (Fed. Cir. 1983) (“when a properly claimed invention meets at least one stated objective, utility under section 101 is clearly shown”).

The courts have expressed a test for utility that hinges on whether an invention provides an “identifiable benefit.” *Juicy Whip*, 185 F.3d at 1366, 51 USPQ.2d at 1702. For analytical purposes, the requirement for an “identifiable benefit” may be broken into two prongs: (1) the invention must have a specific, *i.e.*, not vague or unknown benefit, *In re Brana*, 51 F.3d 1560, 1565, 34 U.S.P.Q.2d 1436, 1440 (Fed. Cir. 1995); and (2) the invention must provide a real world, *i.e.*, practical or “substantial” benefit. *Fujikawa v. Wattanasin*, 93 F.3d 1559, 1563, 39 U.S.P.Q.2d 1895, 1899 (Fed. Cir. 1996). A corollary to this test for utility is that the invention must not be “totally incapable of achieving a useful result,” *i.e.*, the utility must not be incredible or unbelievable. *Brooktree Corp. v. Advanced Micro Devices, Inc.*, 977 F.2d 1555, 1571, 24 U.S.P.Q.2d 1401, 1412 (Fed. Cir. 1992).

Appellant has asserted in the specification that the claimed nucleic acid molecules provide identifiable benefits, for example, use to encode a copalyl diphosphate synthase enzyme (*see, e.g.*, specification at page 16, lines 15-17 and page 210, Table A), as nucleic acid molecule markers and probes (*see, e.g.*, specification at page 46, line 15 through page 50, line 9); to identify and obtain nucleic acid homologues (*see, e.g.*, specification at page 57, line 4 through page 58, line 23); in microarrays as gene-specific targets (*see, e.g.*, specification at page 78, line 1 through page 80, line 7); to identify the presence or absence of a polymorphism (*see, e.g.*, specification at page 60, line 5 through page 73, line 11); use to transform plants (*see, e.g.*, specification at page 84, line 21 through page 102, line 18); to determine the level or pattern of expression of a protein or mRNA associated with that nucleic acid molecule (*see, e.g.*, specification at page 73, line 12 through page 80, line 7); and use to overexpress or suppress a desired protein (*see, e.g.*, specification at page 103, line 7 through page 107, line 3). Any of these utilities described alone is enough to satisfy Section 101. Because Applicants need only establish a single utility to satisfy 35 U.S.C. § 101, and have done so in the present case, the premise of the rejection under Section 101 is incorrect, and the rejection should be reversed.

**(1) The Claimed Nucleic Acid Molecules Provide A Specific Benefit, *i.e.*, They Have Specific Utility**

The specification describes multiple utilities for the present invention, including encoding a copalyl diphosphate synthase or fragment thereof, identifying polymorphisms, determining plant traits and DNA mapping. *See* Specification at page 16, lines 10-14, page 210, Table A and pages 57, *et seq.*, under the heading “Uses of the Agents of the Invention.” Moreover, the specification also discloses additional utilities for the claimed



nucleic acid molecules,<sup>1</sup> including use of the claimed nucleic acid molecules to measure the level of mRNA in a sample,<sup>2</sup> and use as molecular markers.<sup>3</sup>

**(a) Use to Encode a Copalyl Diphosphate Synthase of Fragment Thereof**

For example, one of the utilities disclosed in the specification is use of the claimed nucleic acid molecules to encode a copalyl diphosphate synthase or fragment thereof. Specification at page 16, lines 10-17, page 45, line 14 through page 46, line 14 and Table A. The Examiner acknowledges that “applicant(s) have listed this sequence which is known in the prior art and which has a high percentage similarity (95%, table A) to a claimed sequence, SEQ ID NO: 7.” Final Action at page 4. The Examiner argues however that this utility is not specific or substantial, apparently because “the citation of sequence similarity results in an unpredictable and therefore unreliable correspondence between the claimed nucleotide and the indicated similar nucleotides of known function and therefore lacks support regarding utility and/or enablement.” *Id.* More specifically, the Examiner argues that “[I]t is known for nucleic acids as well as proteins, for example, that even a single nucleotide or amino acid change or mutation can destroy the function of the biomolecule in many instances, albeit not in all cases.” *Id.* While the Examiner

---

<sup>1</sup> Appellant is not relying solely on utility of the mRNA or polypeptide to establish utility of the claimed nucleic acid molecules.

<sup>2</sup> It is standard practice to screen populations of nucleic acids with EST sequences, often attached to a microarray, without characterizing each and every target mRNA. Knowing that the gene corresponding to the claimed nucleic acid molecules is expressed under certain conditions or in certain tissues or at certain levels is in itself useful. For example, such information is useful to detect expression changes in traits of interest, *e.g.*, genes involved in the gibberellin pathway.

<sup>3</sup> One can use the claimed nucleic acid molecules to determine location of a corresponding DNA sequence on a physical map or genetic map location without knowing anything beyond the claimed sequence. The use of molecular markers is a practical activity in the development of nutritionally enhanced or agriculturally enhanced crops. Such markers are useful in, for example, genetic mapping or linkage analysis, marker-assisted breeding, physical genome mapping, transgenic crop production, crop monitoring diagnostics, and gene identification and isolation. As more markers are identified, genetic maps will become more detailed and it will be easier for plant breeders to breed for particular traits.

proceeds to analyze SEQ ID NO: 7 by pointing to publications generally describing the unpredictability of the relationship between sequence and function, the Examiner provides no support to show that SEQ ID NO: 7 does not function as described by the specification.

The Examiner also argues that “it is unpredictable if SEQ ID NO: 7 will successfully encode a functional enzyme in that it is not indicated to be a full-length open reading frame.” Final Action at page 4. Again the Examiner provides no support to show that SEQ ID NO: 7 does not encode a functional copalyl diphosphate synthase enzyme or fragment thereof and attempts to shift the burden to the Appellant.

The specification provides extensive evidence based on sequence identity that the claimed nucleic acid molecules encode a polypeptide having 95% identity to a known copalyl diphosphate synthase. *See, e.g.*, specification at page 210 (Table A). The specification also indicates by way of the description of the enzymatic function of copalyl diphosphate synthase that the specified enzyme has well-known enzymatic function in the art. *See, e.g.*, specification at page 3, lines 1-5. Further a detailed description of the characterization of the specified enzyme and its role in the gibberellin biosynthetic pathway. *See, e.g.*, specification at pages 2-5.

An examiner must accept a utility by an applicant unless the Office has evidence or sound scientific reasoning to rebut the assertion. *See In re Oetiker*, 977 F.2d 1443, 1445, 24 U.S.P.Q.2d 1443, 1444 (Fed. Cir. 1992). “More specifically, when a patent application claiming a nucleic acid asserts a specific, substantial, and credible utility, and bases the assertion upon homology to existing nucleic acids or proteins having an accepted utility, the asserted utility must be accepted by the examiner unless the Office has sufficient evidence or sound scientific reasoning to rebut such as assertion.” Federal Register 66(4):1096, Utility Guidelines (2001). “[A] ‘rigorous correlation’ need not be

shown in order to establish practical utility; ‘reasonable correlation’ is sufficient.” *Fujikawa v. Wattanasin*, 93 F.3d 1559, 1565, 39 U.S.P.Q.2d 1895, 1900 (Fed. Cir. 1996).

The Examiner argues that sequence similarity does not reliably predict a protein’s function in some cases. However, the Examiner admits that this is not true in all cases. The Examiner does not provide any evidence in the Office Actions to support the proposition that SEQ ID NO: 7 does not encode a copalyl diphosphate synthase.

The claimed nucleic acid molecules have been asserted to encode a copalyl diphosphate synthase or fragment thereof. The specification provides ample correlation between the claimed nucleic acid molecule and copalyl diphosphate synthase proteins. Accordingly, the assertion of the use of the claimed nucleic acid molecules to encode a copalyl diphosphate synthase or fragment thereof satisfies the utility requirement of 35 U.S.C. § 101.

#### **(b)Identifying the Presence or Absence of a Polymorphism**

Another of the utilities disclosed in the specification is use of the claimed nucleic acid molecules to identify the presence or absence of a polymorphism. Specification at page 60, line 5 through page 73, line 11. The Examiner argues that this utility, like many of the asserted utilities, is not specific or substantial, *see, e.g.*, Final Action at page 9, but does not provide any support (legal or factual) for the proposition that detection of polymorphisms using the claimed nucleic acid molecules is not a legal utility.

Many of the disclosed utilities in this case, including the detection of polymorphisms, are directly analogous to the utilities of a microscope, *i.e.*, the claimed nucleic acid molecules may be used to locate and measure nucleic acid molecules within a sample, cell, or organism. The Examiner denigrates such utilities by asserting that these utilities are not “useful” because the specification does not describe “what effect an identified polymorphism will have.” *Id.* However, the fact that, *e.g.*, a new and nonobvious microscope or screening assay can be used for learning about products or

processes does not lessen the fact that such “tools” have legal utility. “Many research tools such as gas chromatographs, screening assays, and nucleotide sequencing techniques have clear, specific and unquestionable utility (*e.g.*, they are useful in analyzing compounds).” MPEP § 2107.01 at page 2100-33.

Use of the claimed nucleic acid molecules to detect the presence or absence of polymorphisms is no more legally insufficient than using a gas chromatograph to analyze the chemical composition of a gas – such use determines information about the gas, not the gas chromatograph. Even if the gas chromatograph detects the absence of a particular chemical element in the gas, that finding does not obviate the utility of the gas chromatograph itself. Information has been obtained about the gas.<sup>4</sup> Likewise, the claimed nucleic acid molecules have utility even if the absence of a particular polymorphism is detected. Indeed, the absence of a polymorphism usefully demonstrates that the two (or more) populations being compared share a common genetic heritage.

The claimed nucleic acid molecules have been asserted to work for a specific, *i.e.*, not vague or unknown benefit, to identify the presence or absence of a polymorphism. This benefit is immediately realized directly from the use of the claimed nucleic acids, not from the use of other molecules. Such a proven use that provides an acknowledged known benefit to the public satisfies the utility requirement of 35 U.S.C. § 101.

### **(c) Probes for Other Molecules or Source for Primers**

Other uses for the claimed nucleic acid molecules are as probes for other molecules or as a source of primers or to detect the presence or absence or level of

---

<sup>4</sup> For example, gas sampled from crude oil may be analyzed by gas chromatography for the presence or absence of chlorine, which is toxic to catalysts used in gasoline refining even in very low concentrations. The absence of a peak at the molecular weight of chlorine indicates the absence of chlorine in the sample being tested, thereby providing useful information (no chlorine is present, therefore the catalyst will not be destroyed) to the refinery manager. *See, e.g.*, U.S. Patent No. 6,133,740 entitled “Chlorine Specific Gas Chromatographic Detector.”

expression of copalyl diphosphate synthase in a sample. The Examiner suggests that these uses are not legal utilities because the disclosed utilities “are non-specific uses that are applicable to nucleic acid(s) in general and not particular or specific to the nucleic acids being claimed.” Final Action, at page 9. This is not correct. The specification discloses that the claimed nucleic acid molecules can be used to isolate nucleic acid molecules of other plants and organisms such as alfalfa, *Arabidopsis*, barley, *Brassica*..., sunflower, oil palm, and *Phaseolus*, etc.<sup>5</sup> Specification at page 42, line 20 through page 43, line 2. Moreover, the specification discloses that the claimed sequence can be used to determine the level or pattern of expression of copalyl diphosphate synthase in a sample. Specification at page 73, line 12 through page 74, line 21. The Examiner has not provided any evidence that would reasonably suggest that this cannot be done, and thus has not met the burden of proof required to establish a utility rejection. See *In re Brana*, 51 F.3d 1560, 1567, 34 U.S.P.Q.2d 1436, 1441 (Fed. Cir. 1995). Accord *In re Gaubert*, 524 F.2d 1222, 1225-26, 187 U.S.P.Q. 664, 666 (C.C.P.A. 1975); *In re Langer*, 503 F.2d 1380, 1391, 183 U.S.P.Q. 288, 297 (C.C.P.A. 1974).

One illustrative example of a molecule that can be isolated using a claimed nucleic acid molecule is the promoter of the gene corresponding to that claimed nucleic acid molecule. Appellant has specifically disclosed that one use of the claimed nucleic acid molecules is to initiate a chromosome walk or alternatively in chromosome landing. Specification at page 59, line 1 through page 60, line 4. The Examiner denigrates that utility by asserting that it is not specific because it is generally applicable to any nucleic acid. Final Action at page 9. This is not correct. The claimed nucleic acid molecules are

---

<sup>5</sup> Furthermore, one skilled in the art of hybridization and amplification understands how to design and utilize probes and primers to target a sequence of interest, and therefore it is not necessary for Appellant to provide a laundry list of each and every nucleic acid molecule that can be identified using the claimed nucleic acid molecules.

particularly useful, for example, to identify markers and isolate promoters involved in the gibberellin biosynthetic pathway. *See, e.g.*, specification at page 15, line 6 through page 16, line 9, page 46, line 15 through page 50, line 9, page 59, line 1 through page 60, line 4 and page 208, line 18 through page 209, line 21.

In short, the Examiner suggests that the asserted utilities are legally insufficient simply because other molecules can be used for the same purpose, *e.g.*, chromosome walks. That position is wrong as a matter of law – there is no requirement of exclusive utility in the patent law. *See Carl Zeiss Stiftung v. Renishaw PLC*, 945 F.2d 1173, 1180, 20 U.S.P.Q.2d 1094, 1100 (Fed. Cir. 1991) (“An invention need not be the best or the only way to accomplish a certain result...”). Such an argument would imply that a new golf club has no legal utility because other golf clubs can be used for the same purpose, *i.e.*, hitting golf balls. That position must be rejected as it requires reading “into the patent laws limitations and conditions which the legislature has not expressed,” a practice condemned by the Supreme Court. *See Diamond v. Chakrabarty*, 447 U.S. 303, 308, 206 U.S.P.Q. 193, 196 (1980), *quoting United States v. Dubilier Condenser Corp.*, 289 U.S. 178, 199, 17 U.S.P.Q. 154, 162 (1933).

Moreover, it is factually incorrect that this use is not “specific” to the claimed nucleic acid molecules. The claimed nucleic acid molecules provide a particularly appropriate and demonstrably useful starting point for a walk to isolate promoters in maize plants. *See, e.g.*, specification at page 59, line 1 through page 60, line 4. A random nucleic acid molecule does not provide an equally good starting point to isolate such genes. Furthermore, even if a random nucleic acid molecule provided a better starting point than the claimed nucleic acid molecules, it would not obviate the utility of the claimed nucleic acid molecules. An invention may be “less effective than existing devices but nevertheless meet the statutory criteria for patentability.” *Custom*

*Accessories, Inc. v. Jeffrey-Allan Indus.*, 807 F.2d 955, 960 n.12, 1 U.S.P.Q.2d 1196, 1199 n.12 (Fed. Cir. 1986).

The Examiner has failed to provide evidence, or even to suggest a reason for believing that the claimed nucleic acid molecules could not be so used. Accordingly, the assertion of this utility as a probe for other molecules or as a source of primers satisfies the requirements of 35 U.S.C. § 101. *See In re Brana*, 51 F.3d 1560, 1566, 34 U.S.P.Q.2d 1436, 1441 (Fed. Cir. 1995).

**(d) Claims 10 and 24-25 are separately patentable**

As discussed above, the Examiner has rejected the claims as allegedly lacking utility because “the citation of sequence similarity results in unpredictable and therefore unreliable correspondence between the claimed nucleotide and the indicated similar nucleotides of known function.” Final Action at page 4. However, claims 10 and 24-25 are directed to isolated nucleic acid molecules comprising SEQ ID NO: 7 or its complement or variations thereof. Even if such a basis for rejection was proper, it would not apply to claims 10 and 24-25 which do not recite nucleic acid molecules that “encodes a maize copalyl diphosphate synthase enzyme.” Applicants have provided a specific utility for the claimed invention. That is all that is required.

**(2) The Claimed Nucleic Acid Molecules Provide Practical, Real World Benefits, *i.e.*, They Have Substantial Utility**

The Final Action also appears to assert that the disclosed uses are legally insufficient because they are not “substantial” utilities. Final Action at pages 3-11. The touchstone of “substantial” utility is “real world” or “practical utility.” *See, e.g., Fujikawa v. Wattanasin*, 93 F.3d 1559, 1563, 39 U.S.P.Q.2d 1895, 1899 (Fed. Cir. 1996). “ ‘Practical utility’ is a shorthand way of attributing ‘real world’ value to claimed subject matter. In other words, one skilled in the art can use a claimed discovery in a manner which provides some immediate benefit to the public.” *Nelson v. Bowler*, 626 F.2d 853,

856, 857, 206 U.S.P.Q. 881, 883 (C.C.P.A. 1980) (“tests evidencing pharmacological activity may manifest a practical utility even though they may not establish a specific therapeutic use”).<sup>6</sup>

There can be no question that one skilled in the art can use the claimed nucleic acid molecules in a manner which provides an immediate benefit to the public, for example to detect the presence or absence of polymorphisms or to encode copalyl diphosphate synthase. The detection of polymorphisms provides an immediate benefit to the public because, *e.g.*, it enables a plant breeder to determine the distribution of parental genetic material in the progeny of a cross. This information about a plant’s genetic profile, like the information about a compound’s pharmacological profile in *Nelson*, provides an immediate benefit and thus a practical utility to the public.

Moreover, the use to encode copalyl diphosphate synthase also provide an immediate benefit to the public because it enables a molecular biologist to modify the gibberellin pathway and control a plant’s growth and development. Such modification provides an immediate benefit and thus a practical utility to the public.

Quite apart from the detection of polymorphisms or encoding copalyl diphosphate synthase, there is also no question that the public has recognized the benefits provided by the claimed subject matter, and has attributed “real world” value to such nucleic acid molecules. The utility of ESTs is not merely an academic issue; the real world value of these constructs is self-evident from the growth of a multi-million dollar industry in the United States premised on their usefulness. Like fermentation processes involving bacteria, ESTs and nucleic acid molecules with EST sequences are “industrial product[s]

---

<sup>6</sup> *Accord Cross v. Iizuka*, 753 F.2d 1040, 1050, 224 U.S.P.Q. 739, 747-48 (Fed. Cir. 1985); *Rey-Bellet v. Engelhardt*, 493 F.2d 1380, 1383, 181 U.S.P.Q. 453, 454 (C.C.P.A. 1974).



used in an industrial process – a useful or technical art if there ever was one.” *In re Bergy*, 563 F.2d 1031, 1038, 195 U.S.P.Q. 344, 350 (C.C.P.A. 1977).

The market participants for EST products are primarily sophisticated corporations and highly knowledgeable scientists who are unlikely to pay for useless inventions. *Cf. Raytheon Co. v. Roper Corp.*, 724 F.2d 951, 960, 220 U.S.P.Q. 592, 599 (Fed. Cir. 1983) (“People rarely, if ever, appropriate useless inventions”). Quite simply, the commercial value of these products is proof of their real world value and of the benefits they provide to the public. This evidence cannot be ignored. The patent system was created to serve and foster growth and development in the industrial arts. If the industries themselves recognize and appreciate the value of an invention, it is not for the Patent Office to say that they are mistaken.

### **(3) The Disclosed Utilities Are Credible to One of Skill in the Art**

An assertion of utility must be accepted by the Examiner unless it would not be considered “credible” by a person of ordinary skill in the art. MPEP § 2107 at 2100-29. Cases in which utility was found not to be credible are rare, and usually involve “hare-brained” utilities.<sup>7</sup> A challenge to the credibility of a utility is essentially a challenge directed to operability, and such a challenge must be supported by a clear statement of “factual reasons which would lead one skilled in the art to question the objective truth of

---

<sup>7</sup> Examples of incredible utilities are given in MPEP § 2107.01 at page 2100-34, and include:

an invention asserted to change the taste of food using a magnetic field (*Fregeau v. Mossinghoff*, 776 F.2d 1034, 227 U.S.P.Q. 848 (Fed. Cir. 1985)), a perpetual motion machine (*Newman v. Quigg*, 877 F.2d 1575, 11 U.S.P.Q. 1340 (Fed. Cir. 1989)), a flying machine operating on “flapping or flutter function” (*In re Houghton*, 433 F.2d 820, 167 U.S.P.Q. 687 (C.C.P.A. 1970)), a method for increasing the energy output of fossil fuels upon combustion through exposure to a magnetic field (*In re Ruskin*, 354 F.2d 395, 148 U.S.P.Q. 221 (C.C.P.A. 1966)), uncharacterized compositions for curing a wide array of cancers (*In re Citron*, 325 F.2d 248, 139 U.S.P.Q. 516 (C.C.P.A. 1963)), a method of controlling the aging process (*In re Eltgroth*, 419 F.2d 918, 164 U.S.P.Q. 221 (C.C.P.A. 1970)), and a method of restoring hair growth (*In re Ferens*, 417 F.2d 1072, 163 U.S.P.Q. 609 (C.C.P.A. 1969)).

the statement of operability.” *In re Gaubert*, 524 F.2d 1222, 1225-26, 187 U.S.P.Q. 664, 666 (C.C.P.A. 1975); *see In re Brana*, 51 F.3d 1560, 1567, 34 U.S.P.Q.2d 1436, 1441 (Fed. Cir. 1995); MPEP § 2107.02 at 2100-41.

Applicants have explicitly identified specific and substantial utilities, not only in the specification, but in Applicants’ Response dated December 9, 2003, at pages 8-11. “To violate [35 U.S.C.] 101 the claimed device must be totally incapable of achieving a useful result.” *Brooktree Corp. v. Advanced Micro Devices, Inc.*, 977 F.2d 1555, 1571, 24 U.S.P.Q.2d 1401, 1412 (Fed. Cir. 1992). To date, the Examiner has provided no evidence that the claimed nucleic acid molecules will not work for the disclosed utilities. Unless and until the Examiner can prove that the claimed invention is wholly inoperative, the rejection must be withdrawn.

In view of the above, Applicants contend that the claimed nucleic acid molecules are supported by credible, specific, and substantial utilities disclosed in the specification. Moreover, the Examiner has failed to raise any credible evidence challenging the presently asserted utilities. Consequently, the rejection of pending claims 10 and 20-21 and 24-25 under 35 U.S.C. §101 is improper and should be reversed.

### **C. The Claimed Nucleic Acids Are Enabled by the Specification**

The enablement of the claimed nucleic acid molecules has been challenged. Pending claims 10 and 20-25 stand rejected as not enabled by the specification, because the claimed nucleic acid molecules allegedly lack utility and therefore cannot be enabled. Final Action at page 5. This rejection is erroneous and has been overcome by the arguments stated above regarding utility because it is well-established law that “the enablement requirement is met if the description enables any mode of making and using the invention.” *Johns Hopkins University v. CellPro*, 152 F.3d 1342, 1361, 47 U.S.P.Q.2d 1705, 1719 (Fed. Cir. 1998) (emphasis added), *quoting Engel Indus. v. Lockformer Co.*, 946 F.2d 1528, 1533, 20 U.S.P.Q.2d 1300, 1304 (Fed. Cir. 1991).

Unless and until the Examiner comes forth with evidence to rebut the objective truth of the utilities disclosed in the specification, this enablement rejection must be withdrawn as improper. *See In re Wright*, 999 F.2d 1557, 1561-62, 27 U.S.P.Q.2d 1510, 1513 (Fed. Cir. 1993); *Ex parte Lemak*, 210 U.S.P.Q. 306, 307 (Bd. App. 1981) (“pure conjecture” does not substantiate rejection for lack of enablement).

The Final Action additionally alleges that “[t]he claims contain subject matter which was not described in the specification in such a way as to enable one skilled in the art... to make the invention.” Final Action at page 11. Appellant asserts that an analysis of the criteria presented by *In re Wands* supports Appellant’s position that no undue experimentation would be required to make and use the claimed invention for the uses disclosed in the specification. *See In re Wands*, 858 F.2d 731, 737, 8 U.S.P.Q.2d 1400, 1404 (Fed. Cir. 1998).

The first *Wands* criterion is the quantity of experimentation necessary. The “make-and-test” quantum of experimentation is reduced by the extensive knowledge, *e.g.*, of conservative nucleotide substitutions, identification of an active site, and conserved regulatory elements, to which a person of ordinary skill in the art has access. The Examiner generally asserts that undue experimentation would be required by the skilled artisan to use the instant invention. Final Action at page 14. However, one skilled in the art is sufficiently guided by Applicants’ disclosure, which sets forth nucleic acid molecules and methods of use thereof in the production of transformed cells and plants. Further, performing routine and well-known steps, such as sequence alignment protocols, transformations and gene expression analysis, cannot create undue experimentation even if it is laborious. *See In re Angstadt*, 537 F.2d 498, 504, 190 USPQ 214, 218-219 (C.C.P.A. 1976).

The second and third *Wands* criteria relate to the amount of direction or guidance given, and the presence or absence of working examples. Again, the specification

provides evidence of sequence identity and hybridization conditions, discusses the use of the claimed nucleic acid molecules to encode a copalyl diphosphate synthase or fragment thereof and discusses the use of the claimed nucleic acid sequence to isolate additional sequences within a genome. *See, e.g.*, Specification at pages 41, line 6 through page 42, line 2, Examples 1-4, the sequence listing and Table A. Based on such disclosure, one of ordinary skill in the art would be enabled to make and use the invention commensurate in scope with the claims.

The fourth, fifth, and sixth *Wands* criteria focuses on the nature of the invention, the state of the art, and the relative skill in the art. The specification provides a detailed description of the nucleic acid sequences required by the claims, and further describes the preparation of constructs and methods of use related thereto. *See, e.g.*, specification at page 84, line 21 through page 103, line 11, page 107, line 4 through page 119, line 16 and Table A (describing nucleic acid molecules of the present invention as encoding a copalyl diphosphate synthase), and page 93, line 15 through page 103, line 11 (describing use of the claimed nucleic acid molecules in methods of transforming plants). Practitioners in this art are guided by considerable knowledge and resources on the conditions and approaches that can be utilized to identify, confirm, and introduce into other hosts, nucleic acid and amino acid sequences.

The seventh criterion considers the predictability of the art. Appellant respectfully asserts, as discussed *supra*, that the specification discloses sufficient guidance to render the results of transformations with the claimed nucleic acid molecules predictable. *See, e.g.*, specification at page 84, line 21 through page 103, line 11. Furthermore, the specification provides sufficient guidance to one of skill in the art to decipher the information necessary to make and use the claimed nucleic acid molecules. *See, e.g.*, specification at page 2, line 9 through page 5, line 18 (describing nucleic acid

molecules and enzymes involved in the gibberellin biosynthetic pathway), and page 73, line 12 through page 80, line 7 (citing methods for assaying gene expression).

The eighth criterion focuses on the breadth of the claims. Enablement is satisfied when the disclosure “adequately guide[s] the art worker to determine, without undue experimentation, which species among all those encompassed by the claimed genus possess the disclosed utility”. See *In re Vaeck*, 947 F.2d 488, 496, 20 U.S.P.Q.2d 1438, 1445 (Fed. Cir. 1991). In the present case, one of skill in the art is specifically guided by the disclosure to look to, *e.g.*, sequence identity data in making that determination.

The Examiner has not met the evidentiary burden to impose an enablement rejection. A specification that discloses how to use a claimed invention “must be taken as in compliance with the enabling requirement of the first paragraph of § 112 unless there is reason to doubt the objective truth of the statements contained therein.” *In re Brana*, 51 F.3d 1560, 1566, 34 U.S.P.Q.2d 1436, 1441 (Fed. Cir. 1995), *quoting In re Marzocchi*, 439 F.2d 220, 223, 169 U.S.P.Q. 367, 369 (C.C.P.A. 1971) (emphasis in original).

The Examiner has provided no evidence supporting the rejection of why the specification allegedly fails to enable the nucleic acid molecules of claims 10 and 20-21 and 24-25. See *In re Wright*, 999 F.2d 1557, 1561-62, 27 U.S.P.Q.2d 1510, 1513 (Fed. Cir. 1993); *Ex parte Lemak*, 210 U.S.P.Q. 306, 307 (B.P.A.I. 1981) (“pure conjecture” does not substantiate rejection for lack of enablement). Therefore, because the above analysis illustrates that the specification clearly enables at least the methods of making and using the invention as set forth in the Examples, and the claims, the enablement requirement has been satisfied. Cf. *Johns Hopkins University v. CellPro*, 152 F.3d 1342, 1361, 47 U.S.P.Q.2d 1705, 1719 (Fed. Cir. 1998) (“the enablement requirement is met if the description enables any mode of making and using the invention”) (emphasis added), *quoting Engel Indus. v. Lockformer Co.*, 946 F.2d 1528, 1533, 20 U.S.P.Q.2d 1300, 1304

(Fed. Cir. 1991). Accordingly, the rejection of claims 10 and 20-21 and 24-25 under 35 U.S.C. § 112, first paragraph is improper and should be reversed.

**D. The Specification Provides an Adequate Written Description of the Claimed Invention**

Despite the Examiner's acknowledgement that the specification discloses the sequence of SEQ ID NO: 7 the adequacy of the written description of claims 10 and 20-25 has been challenged by the Examiner because the claimed subject matter was allegedly "not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention." Final Action, at page 14. The basis for the Examiner's challenge is that "the claims are directed to encompass gene sequences of any magnitude and/or content comprising SEQ ID NO: 7 or of SEQ ID NO: 7; a genus that is extremely large while that which is disclosed is a single sequence." *Id.* The Examiner also argues that "the specification does not disclose the content of the sequence that differentiates between ... the instant maize enzyme and a non-maize enzyme." *Id.* at page 15. In addition, the Examiner rejects the claims based on the percent identity language arguing that "[t]hese claims read on a very broad and highly variable genus of nucleic acid molecules which includes variants, homologs, and mutants of SEQ ID NO:7, with either retained or altered function." *Id.* The Examiner further argues that "due to the 'comprising' claim language of claim 10, claim 10 encompasses sequences of any magnitude and/or content comprising SEQ ID NO: 7." *Id.* This is not a proper basis for a written description rejection of a "comprising" claim. If it was, every "comprising" claim ever written would be invalid for failing to describe every nuance of the claimed invention. Furthermore, the specification demonstrates to one skilled in the art that Appellant was in possession of the claimed genera of nucleic acid molecules.

**(1) The Specification Reflects Appellant's Possession of the Claimed Invention**

The purpose of the written description requirement is to ensure that the inventors had possession of the claimed subject matter, *i.e.*, to ensure that the inventors actually invented what is claimed. *Gentry Gallery Inc. v. Berkline Corp.*, 134 F.3d 1473, 1479, 45 U.S.P.Q.2d 1498, 1503 (Fed. Cir. 1998); *Lockwood v. American Airlines*, 107 F.3d 1565, 1572, 41 U.S.P.Q.2d 1961, 1966 (Fed. Cir. 1997); *In re Alton*, 76 F.3d 1168, 1172, 37 U.S.P.Q.2d 1578, 1581 (Fed. Cir. 1996). If a person of ordinary skill in the art would, after reading the specification, understand that the inventors had possession of the claimed invention, even if every nuance of the invention was not expressly described, then the written description requirement has been met. *In re Alton*, 76 F.3d at 1175, 37 U.S.P.Q.2d at 1584. After reading the present specification, a person of ordinary skill in the art would understand that Appellant had possession of nucleic acid molecules comprising SEQ ID NO: 7 as well as complements and variations thereof, and therefore, the claimed invention.

Appellant has provided the nucleic acid sequence required by the claims, *i.e.*, SEQ ID NO: 7, as well as, for example, vectors comprising the nucleic acid sequence (*see, e.g.*, specification at page 84, line 21 through page 93, line 14), hybridization conditions which may be used with the nucleic acid molecules of the present invention (*see, e.g.*, specification at page 38, line 13 through page 40, line 4), and other systems that may be used to introduce the claimed nucleic acid molecules into a host cell (*see, e.g.*, specification at page 107, line 4 through page 139, line 2). The fact that the claims at issue are intended to cover molecules that include the recited sequence joined with additional sequences does not mean that Appellant was any less in possession of the

claimed nucleic acid molecules.<sup>8</sup> It is well-established that use of the transitional term “comprising” leaves the claims “open for the inclusion of unspecified ingredients even in major amounts.” *Ex parte Davis*, 80 U.S.P.Q. 448, 450 (B.P.A.I. 1948). *Accord PPG Indus. v. Guardian Indus.*, 156 F.3d 1351, 1354, 48 U.S.P.Q.2d 1351, 1353-54 (Fed. Cir. 1998); *Moleculon Research Corp. v. CBS*, 793 F.2d 1261, 1271, 229 U.S.P.Q. 805, 812 (Fed. Cir. 1986).

Appellant has provided in the present disclosure not only the nucleotide sequence required by the claims (i.e. SEQ ID NO: 7), but also several variations including and directed to the claimed nucleic acid molecules. For example, the present specification describes vectors comprising the claimed nucleic acid molecules (specification at page 84, line 21 through page 93, line 14), and describes how to make the nucleotide sequences and libraries from which they were originally purified. *See, e.g.*, Examples page 144, line 18, *et. seq.* Furthermore, the addition of extra nucleotides or detectable labels to the disclosed nucleotide sequence (SEQ ID NO: 7) is readily envisioned by one of ordinary skill in the art upon reading the present specification,<sup>9</sup> in particular at page 52, lines 7-18 (describing fusion peptide molecules encoded by the claimed nucleic acid molecules), page 38, lines 1-5 (describing sequences with labels to facilitate detection), page 80, line 8 through page 81, line 22 (describing site-directed mutagenesis) and page 138, line 17 through page 139, line 2 (citing references describing the construction, manipulation and isolation of nucleic acid macromolecules).

---

<sup>8</sup> If the Examiner is arguing that no possession is shown because the precise claim language is not used in the specification, then he goes beyond what is required by the law. It is well-settled that the description of a claimed invention need not be *in ipsius verbis*. *Gentry Gallery v. Berkline Corp.*, 134 F.3d 1473, 1479, 45 U.S.P.Q.2d 1498, 1503 (Fed. Cir. 1998); *In re Alton*, 76 F.3d 1168, 1175, 37 U.S.P.Q.2d 1578, 1583 (Fed. Cir. 1996); *Martin v. Johnson*, 454 F.2d 746, 751, 172 U.S.P.Q. 391, 395 (C.C.P.A. 1972).

<sup>9</sup> It is established patent jurisprudence that Applicants need not teach “conventional and well-known genetic engineering techniques.” *E.g., Ajinomoto Co. v. Archer-Daniels-Midland Co.*, 228 F.3d 1338, 1345, 56 U.S.P.Q.2d 1332, 1337 (Fed. Cir. 2000).



Moreover, the court determined, in *Enzo Biochem, Inc. v. Gen-Probe Inc.*, 296 F.3d 1316, 1321, 63 U.S.P.Q.2d 1609, 1610 (Fed. Cir. 2002), that the written description inquiry is a factual one determined on a case-by-case basis and that, in a given disclosure, “it may well be that various subsequences, mutations, and mixtures of those sequences are also described to one of skill in the art.” *Enzo*, 296 F.3d at 1326-1327, 63 U.S.P.Q.2d at 1615. Furthermore, it is well established that claims “may be broader than the specific embodiment disclosed in a specification. *Ralston-Purina Co. v. Far-mor-Co*, 772 F.2d 1570, 1575, 227 U.S.P.Q. 177, 179 (Fed. Cir. 1985) (*quoting In re Rasmussen*, 650 F.2d 1212, 1215, 211 U.S.P.Q. 323, 326 (C.C.P.A. 1981).

## **(2) Appellant Has Described the Claimed Invention**

The Final Action asserts that “[b]eyond providing the sequence data for SEQ ID NO:7, the specification provides no teaching or guidance which correlates the sequence of SEQ ID NO: 7 to its function, which amino acids in the protein encoded by SEQ ID NO: 7 are critical to its function, or how to modify SEQ ID NO: 7 to obtain any specific homolog, mutant or variant.” Final Action at page 15. The Examiner appears to assert that each nucleic acid molecule within the claimed genus must be described by its complete structure. These assertions are totally unfounded. The Federal Circuit has elucidated a test for written description wherein a genus of nucleic acids may be described by a structural feature that distinguishes members of the claimed genus from non-members of the claimed genus. *Regents of the University of California v. Eli Lilly and Co.*, 119 F.3d 1559, 1568-69, 43 U.S.P.Q.2d 1398, 1406 (Fed. Cir. 1997). Appellant has satisfied that test for written description.

In particular, Appellant has disclosed structural features, for example, the nucleotide sequences of SEQ ID NO: 7. The respective structural feature (for example, the nucleotide sequence of SEQ ID NO: 7) is shared by every nucleic acid molecule in the claimed genus, and it distinguishes the members of the claimed genus from non-

members. For example, if a nucleic acid molecule such as an mRNA contains the nucleotide sequence of SEQ ID NO: 7, then it is a member of the claimed genus of nucleic acid molecules comprising a nucleic acid sequence of SEQ ID NO: 7. *See*, claim 10. If a nucleic acid molecule does not contain SEQ ID NO: 7, then it is not a member of that claimed genus. The presence of other nucleotides at either end of the recited sequence will not interfere with the recognition of a claimed nucleic acid molecule as such – it either contains the nucleotides of SEQ ID NO: 7 or it does not. One skilled in the art, after reading the present specification, would clearly know if a nucleic acid molecule contains the recited nucleotide sequence.

Moreover, this argument applies with equal force to every genus of the claimed nucleic acid molecule. For example, if a nucleic acid molecule such as an mRNA, comprises a nucleotide sequence having 98% identity to SEQ ID NO: 7, then it is a member of the genus of nucleic acid molecules having 98% identity to SEQ ID NO: 7. *See*, claim 24. If a nucleic acid molecule does not fall within the recited percent identity to SEQ ID NO: 7, then it is not a member of that claimed genus. Finally, if a nucleic acid molecule hybridizes under the recited conditions, then it is a member of the genus of nucleic acid molecules hybridizing under those conditions to SEQ ID NO: 7. *See* claim 20. The presence of other nucleotides at either end of the recited sequence will not interfere with the recognition of a claimed nucleic acid molecule as such – it either contains the nucleotides having the recited percent identity, or hybridizes to , the nucleic acid sequence of SEQ ID NO: 7 or it does not. One skilled in the art, after reading the present specification, would clearly know if a nucleic acid molecule contains the recited nucleotide sequence.

**(3) Claims 10 and 24-25 are separately patentable**

The Examiner argues that “[c]laims 20 and 21 require the isolated nucleic acid to encode a maize copalyl diphosphate synthase enzyme or fragment thereof.” Final Action

at page 15. The Examiner provides no support as to why one of skill in the art would not be able to recognize a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 7 or complements or variations thereof. The specification describes SEQ ID NO: 7, hybridization conditions and sequences with the claimed percent identities. *See, e.g.*, specification at page 38, line 13 through page 41, line 5 and in the sequence listing. The skilled artisan would recognize that Appellant had possession of a nucleic acid sequence comprising SEQ ID NO: 7, as well as complements and variations thereof. Moreover, such a basis for rejection, even if valid, would not apply to claims 10 and 24-25, which do not recite “a maize copalyl diphosphate synthase enzyme or fragment thereof.” The Examiner has not presented any evidence to contradict this. Appellant has provided an adequate written description for the claimed invention. That is all that is required.

**(4) Pending Claims 10 and 20-21 and 24-25 are supported by a written description**

In light of all of the arguments above, claims 10 and 20-21 and 24-25 are supported by an adequate written description pursuant to the requirements of 35 U.S.C. § 112, and the rejection should be reversed.

**E. The Claims Particularly Point Out and Distinctly Claim the Subject Matter Which Appellants Regard as Their Invention**

Pending claims 22-25 stand rejected under 35 U.S.C. § 112, second paragraph as being indefinite. Final Action at page 18-19. More specifically, the Examiner indicates that the recitation of the phrase “comprises a nucleic acid sequence that shares between 100% and 90% sequence identity with SEQ ID NO: 7” is vague and indefinite. *Id.* According to the Examiner, “[I]t is unclear as to which nucleic acid sequence of the elected sequence is required [to] have 90%-100% identity and be comprised within the claimed isolated sequence.” *Id.* The Examiner’s position is unfounded.

The claims are to be read in light of the specification. *See In re Vogel*, 422 F.2d 438, 441, 164 U.S.P.Q. 619, 622 (C.C.P.A. 1970). The test for determining whether terms in a given claim are indefinite is whether one skilled in the art would understand what is claimed. *Amgen, Inc. v. Chugai Pharmaceutical Co., Ltd.*, 927 F.2d 1200, 18 U.S.P.Q.2d 1016 (Fed. Cir. 1991), *cert. denied*, 112 S. Ct. 169 (1991). Furthermore, it is axiomatic that claims are always construed in light of the specification, of which they are a part. *Netword L.L.C. v. Centraal Corp.*, 242 F.3d 1347, 1352, 58 U.S.P.Q.2d 1076, 1079 (Fed. Cir. 2001); *Slimfold Mfg. Co. v. Kinkead Indus., Inc.*, 810 F.2d 1113, 1118, 1 U.S.P.Q. 2d 1563, 1566 (Fed. Cir. 1987). The specification describes, for example, appropriate hybridization conditions and percent identity. *See, e.g.*, Specification at page 39, line 11 through page 40, line 19. A person skilled in the art, reading the specification and the claims as a whole, would readily understand the recited phrase. As such, the phrase “comprises a nucleic acid sequence that shares between 100% and 90% sequence identity with SEQ ID NO: 7” satisfies the requirements of 35 U.S.C. 112, second paragraph and the rejection should be reversed.

#### **F. The Claimed Nucleic Acid Molecules Are Novel**

Claims 20-25 have been erroneously rejected under 35 U.S.C. § 102(b) over GenBank Accession No. L37750 (gi 576885; 03-Aug-1995) (“GenBank L37750”). Claims 22-23 have been cancelled in the after final amendment filed herewith. Accordingly, Appellant will address this rejection as it pertains to claims 20-21 and 24-25. For a prior art reference to anticipate in terms of 35 U.S.C. §102, every element of the claimed invention must be identically shown in a single reference. *Diversitech Corp. v. Century Steps, Inc.*, 850 F.2d 675, 677, 7 U.S.P.Q. 2d 1315, 1317 (Fed. Cir. 1988). *See also Kalman v. Kimberly Clark Corp.*, 713 F.2d 760, 771 (Fed. Cir. 1983). GenBank L37750 does not teach every element of the claimed invention.

**(1) GenBank Does Not Teach the Claimed Invention**

**(a) GenBank L37750 Does Not Teach SEQ ID NO: 7 or a Complement Thereof**

The Final Action alleges that GenBank L37750 discloses SEQ ID NO: 7, which “has 95% identity to SEQ ID NO: 7.” Final Action at page 19. The Final Action further states that “the sequence also shares between 90% and 100% identity with SEQ ID NO: 7” and, as such, anticipates claim 22<sup>10</sup>. *Id.* The Final Action also alleges “the sequence encodes a kaurene synthase A (copalyl diphosphate synthase).” In addition, the Examiner argues that “[w]ith the high sequence homology, the sequence would hybridize to a sequence of SEQ ID NO: 7 and encode a copalyl diphosphate enzyme” thus presumably anticipating claims 20 and 21. *Id.* Finally, the Final Action asserts that “[d]ue to the claims 22-25 requiring only that a nucleic acid sequence share a percent identity with SEQ ID NO: 7, as few as 2 bp of the instant accession number that align 100% anticipate the claimed nucleic acids.” *Id.*

GenBank L37750 does not disclose SEQ ID NO: 7 or a complement or variation thereof within the pending claims and, as such, cannot anticipate the claimed invention. The Examiner has applied an untenable interpretation of pending claims 24-25 to cover small fragments of the specifically claimed nucleic acid molecules, *i.e.*, molecules as short as one dimer, or two nucleotides, and thus concludes that the claims are anticipated by the cited reference. This is not correct.

Whatever else GenBank L37750 discloses, it does not disclose or describe a nucleic acid sequence comprising SEQ ID NO: 7. As such, the Examiner has failed to demonstrate that the reference discloses SEQ ID NO: 7 or a complement thereof and thus

---

<sup>10</sup> Appellant notes that the Final Action refers to claim 21. However, claim 21 recites “[t]he substantially purified nucleic acid molecule of claim 20, wherein said first nucleic acid molecule comprises SEQ ID NO: 7 or its complement.” Claim 22 however, refers to the recited percent identity language referred to by the Examiner. Accordingly, Appellant treats the recitation of claim 21 as a typographical error.

the rejection of pending claims 20-21 and 24-25 over GenBank L37750 must be withdrawn.

**(b) GenBank L37750 Does Not Teach a Nucleic Acid Molecule that Specifically Hybridizes to a Nucleic Acid Molecule Having a Sequence of SEQ ID NO: 7 or a Complement Thereof**

The Final Action alleges that the nucleic acid molecule cited in GenBank L37750 would hybridize to a nucleic acid molecule having a nucleic acid sequence of SEQ ID NO: 7 or a complement thereof. The Examiner has rejected claims 20-21 as anticipated by GenBank L37750 presumably because nucleotide fragments of GenBank L37750 would allegedly hybridize to fragments of SEQ ID NO: 7 or a complement thereof. Final Action at page 19.

The specification includes appropriate stringency conditions for a nucleic acid molecule of the present invention to specifically hybridize to another nucleic acid molecule “at 6.0 X sodium chloride/sodium citrate (SSC) at about 45°C, followed by a wash of 2.0 X SSC at 50°C”. Specification at page 39, line 11 through page 40, line 4. The specification further states that “the salt concentration in the wash step can be selected from a low stringency of about 2.0 X SSC at 50°C to a high stringency of about 0.2 X SSC at 50°C. In addition, the temperature in the wash step can be increased from low stringency conditions at room temperature, about 22°C, to high stringency conditions at about 65°C.” *Id.* The Examiner has presented no evidence to support the assertion that GenBank L37750 would specifically hybridize to a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 7 under the conditions provided for in the specification.

No evidence, extrinsic or otherwise, has been presented by the Examiner in support of the proposition that GenBank L37750 would specifically hybridize to a nucleic acid molecule having a nucleic acid sequence of SEQ ID NO: 7 or a complement thereof.

Instead of providing evidence, the Examiner appears to shift the burden of proof to Applicants to provide evidence that the nucleic acids are not identical and would not hybridize to the claimed nucleic acid molecules. Therefore, the Examiner has failed to demonstrate that the reference discloses SEQ ID NO: 7 or a complement thereof, or that the sequence cited in the reference would hybridize to SEQ ID NO: 7 or a complement thereof, and thus the rejection of claims 20-21 over GenBank L37750 must be withdrawn.

**(2) The Sigma Reference Does Not Anticipate Claims 20-21 and 24-25**

Claims 20-25 have been erroneously rejected under 35 U.S.C. § 102(b) over products O1256 and O4378 of the 1993 Sigma Chemical Catalogue Company (collectively "Sigma Catalogue"). Claims 22-23 have been cancelled in the after final amendment filed herewith. Accordingly, Appellant will address this rejection as it pertains to claims 20-21 and 24-25. This reference does not anticipate claims 20-21 and 24-25. For a prior art reference to anticipate in terms of 35 U.S.C. §102, every element of the claimed invention must be identically shown in a single reference. *Diversitech Corp. v. Century Steps, Inc.*, 850 F.2d 675, 677, 7 U.S.P.Q. 2d 1315, 1317 (Fed. Cir. 1988). *See also Kalman v. Kimberly Clark Corp.*, 713 F.2d 760, 771 (Fed. Cir. 1983). The Sigma Catalogue does not teach every element of the claimed invention.

**(a) The Sigma Catalogue Does Not Teach SEQ ID NO: 7 or a Complement Thereof**

The Final Action alleges that "these oligonucleotides are fragments in length that are encompassed by the instantly claimed nucleic acids. They thus anticipate instant claims via segments therein which are poly T segments or poly A segments present in SEQ ID NO: 7." Final Action at page 20. The Final Action further states that "[d]ue to claims 22-25 requiring only that a nucleic acid sequence share a percent identity with

SEQ ID NO: 7, as few as 2 bp of the instant accession number that align 100% anticipate the claimed nucleic acids.” *Id.*

The Sigma Catalogue does not disclose SEQ ID NO: 7 or a complement thereof and, as such, cannot anticipate the claimed invention. The Examiner has applied an untenable interpretation of the claims to cover small fragments of the specifically claimed nucleic acid molecules, *i.e.*, molecules as short as two nucleotides, and thus concludes that the claims are anticipated by the cited reference. This is not correct.

It is axiomatic that claims are to be read in light of the specification. *See in re Vogel*, 422 F.2d 438, 441, 164 U.S.P.Q. 619, 622 (C.C.P.A. 1970). Nowhere in the present claims does it state that a nucleic acid sequence or complement of a nucleic acid molecule of the present invention may be as short as two nucleotides. The Examiner has not read the claims in light of the specification, as required by law, but rather has attempted to employ an untenable interpretation of the claim language. As such, the Examiner has failed to demonstrate that the reference discloses SEQ ID NO: 7 or a complement thereof and thus the rejection of claims 20-21 and 24-25 over products O1256 and O4378 of the 1993 Sigma Chemical Catalogue Company must be withdrawn.

**(b) The Sigma Catalogue Does Not Teach a Nucleic Acid Molecule that Specifically Hybridizes to a Nucleic Acid Molecule Having a Sequence of SEQ ID NO: 7 or a Complement Thereof**

In addition to the allegations by the Examiner noted above that products O1256 and O4378 are encompassed by the instantly claimed nucleic acids.” Final Action at page 20.

The specification includes appropriate stringency conditions for a nucleic acid molecule of the present invention to specifically hybridize to another nucleic acid molecule “at 6.0 X sodium chloride/sodium citrate (SSC) at about 45°C, followed by a wash of 2.0 X SSC at 50°C”. Specification at page 39, line 11 through page 40, line 4.




The specification further states that “the salt concentration in the wash step can be selected from a low stringency of about 2.0 X SSC at 50°C to a high stringency of about 0.2 X SSC at 50°C. In addition, the temperature in the wash step can be increased from low stringency conditions at room temperature, about 22°C, to high stringency conditions at about 65°C.” *Id.* The Examiner has presented no evidence to support the assertion that any of the products cited in the Sigma Catalogue would specifically hybridize to a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 7 under the conditions provided for in the specification. To the contrary, the examiner has alleged that the fragments of the nucleic acid molecules cited in the Sigma Catalogue will hybridize to the claimed nucleic acid molecules, but has not alleged that any of the nucleic acids cited in the reference would hybridize to a nucleic acid molecule having a nucleic acid sequence of SEQ ID NO: 7 or a complement thereof.

No evidence, extrinsic or otherwise, has been presented by the Examiner in support of the proposition that any of the chemical compositions provided in the Sigma Catalogue would specifically hybridize to a nucleic acid molecule having a nucleic acid sequence of SEQ ID NO: 7 or a complement thereof. Instead of providing evidence, the Examiner appears to shift the burden of proof to Applicants to provide evidence that the nucleic acids are not identical and would not hybridize to the claimed nucleic acid molecules. Therefore, the Examiner has failed to demonstrate that the reference discloses SEQ ID NO: 7 or a complement thereof, or that the chemicals cited in the reference would hybridize to SEQ ID NO: 7 or a complement thereof, and thus the rejection of claims 20-21 and 24-25 over products O1256 and O4378 of the 1993 Sigma Chemical Catalogue Company must be withdrawn.

**CONCLUSION**

In view of the foregoing, it is respectfully requested that the Board of Patent Appeals and Interferences reverse the Rejections and that the subject application be allowed forthwith.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'T. E. Holsten', written over a horizontal line.

Thomas E. Holsten (Reg. No. 46,098)  
David R. Marsh (Reg. No. 41,408)

Date: November 5, 2004

Of Counsel

Lawrence M. Lavin, Jr. (Reg. No. 30,768)  
Thomas E. Kelley (Reg. No. 29,938)  
Monsanto Company

ARNOLD & PORTER LLP  
555 Twelfth Street, NW  
Washington, DC 20004-2402  
(202) 942-5000 telephone  
(202) 942-5999 facsimile

**APPENDIX A**  
**Claims as Pending**


10. An isolated nucleic acid molecule comprising the nucleic acid sequence of SEQ ID NO: 7 or its complement.
20. A substantially purified first nucleic acid molecule that encodes a maize copalyl diphosphate synthase enzyme or fragment thereof, wherein said first nucleic acid molecule comprises a nucleic acid sequence that hybridizes under conditions of 6.0 X sodium chloride/sodium citrate (SSC) at about 45°C, followed by a wash of 2.0 X SSC at 50°C to a second nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 7 or its complement.
21. The substantially purified first nucleic acid molecule of claim 20, wherein said first nucleic acid molecule comprises SEQ ID NO: 7 or its complement.
22. A substantially purified nucleic acid molecule, wherein said nucleic acid molecule comprises a nucleic acid sequence that shares between 100% and 90% sequence identity with SEQ ID NO: 7 or its complement.
23. The substantially purified nucleic acid molecule of claim 22, wherein said nucleic acid sequence shares between 100% and 95% sequence identity with SEQ ID NO: 7 or its complement.
24. The substantially purified nucleic acid molecule of claim 23, wherein said nucleic acid sequence shares between 100% and 98% sequence identity with SEQ ID NO: 7 or its complement.
25. The substantially purified nucleic acid molecule of claim 24, wherein said nucleic acid sequence shares between 100% and 99% sequence identity with SEQ ID NO: 7 or its complement.

**APPENDIX B**  
**Claims as Pending Upon Entry of the Amendment Filed Herewith**

10. An isolated nucleic acid molecule comprising the nucleic acid sequence of SEQ ID NO: 7 or its complement.
  
20. A substantially purified first nucleic acid molecule that encodes a copalyl diphosphate synthase enzyme or fragment thereof, wherein said first nucleic acid molecule comprises a nucleic acid sequence that hybridizes under conditions of 6.0 X sodium chloride/sodium citrate (SSC) at about 45°C, followed by a wash of 2.0 X SSC at 50°C to a second nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 7 or its complement.
  
21. The substantially purified first nucleic acid molecule of claim 20, wherein said first nucleic acid molecule comprises SEQ ID NO: 7 or its complement.
  
24. A substantially purified nucleic acid molecule, wherein said nucleic acid molecule comprises a nucleic acid sequence that shares between 100% and 98% sequence identity with SEQ ID NO: 7 or its complement.
  
25. The substantially purified nucleic acid molecule of claim 24, wherein said nucleic acid sequence shares between 100% and 99% sequence identity with SEQ ID NO: 7 or its complement.

## **APPENDIX C**

### **Related Proceedings Appendix**



The opinion support of the decision being entered today was not written for publication and is not binding precedent of the Board.

Paper No. 17


**UNITED STATES PATENT AND TRADEMARK OFFICE**

**BEFORE THE BOARD OF PATENT APPEALS  
AND INTERFERENCES**

Ex parte DANE K. FISHER, and RAGHUNATH V. LALGUDI

Appeal No. 2002-2046  
Application No. 09/619,643

HEARD: March 16, 2004



Before WILLIAM F. SMITH, ADAMS, and GRIMES, Administrative Patent Judges.


ADAMS, Administrative Patent Judge.

DECISION ON APPEAL

This is a decision on the appeal under 35 U.S.C. § 134 from the examiner's final rejection of claim 1, the only claim pending in the application, reproduced below:

1. A substantially purified nucleic acid molecule that encodes a maize protein or fragment thereof comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1 through SEQ ID NO:5.

The examiner does not rely on a reference.



### GROUND OF REJECTION

Claim 1 stands rejected under 35 U.S.C. § 101 as lacking utility and § 112, first paragraph, for lack of enablement based on the finding of lack of utility. Claim 1 also stands rejected under 35 U.S.C. § 112, first paragraph, as the specification fails to provide an adequate written description of the claimed invention. We affirm the utility and enablement rejections. We reverse the written description rejection.

### BACKGROUND

The subject matter of the present appeal is directed to expressed sequence tags (ESTs). See Specification, page 15, lines 9-10. ESTs "are short sequences of randomly selected clones from a cDNA (or complementary DNA) library which are representative of the cDNA inserts of these randomly selected clones." Specification, page 1.

As set forth at page 9, lines 2-4, of appellants' specification "[t]he present invention provides a substantially purified nucleic acid molecule that encodes a maize protein or fragment thereof comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1 through SEQ ID NO: 32236." Of these 32,236 nucleic acid sequences, the originally filed claims were directed to SEQ ID NO: 1 through SEQ ID NO: 4,013. On January 26, 2001 (Paper No. 4), the examiner entered a Restriction requirement into the record, requiring, inter alia, appellants "to elect up to 5 nucleic acid sequences" for consideration on the merits. Paper No. 4, page 3. In response, appellants elected SEQ ID NO:1 through SEQ ID NO:5. The ESTs set forth in SEQ ID NO: 1 through SEQ ID NO:

5 are disclosed to be obtained from cDNA library LIB3115 "generated from maize (RX601, Asgrow Seed Company, Des Moines, Iowa U.S.A.) pooled leaf tissue...." Specification, pages 79-80, Example 1.

The specification sets forth a number of utilities for the nucleic acid molecules of SEQ ID NO: 1 through SEQ ID NO: 5 which are summarized by the examiner (Answer, bridging paragraph, pages 5-6) as follows:

The specification teaches that the nucleic acids may be used to produce a plant containing reduced levels of a protein (pg. 11), determining an association between a polymorphism and a plant trait (pg. 11), isolating a genetic region or nucleic acid (pg. 11), determining a level or pattern in a plant cell of a protein in a plant (pg. 11), determining a mutation in a plant whose presence is predictive of a mutation affecting a level or pattern of a protein (pg. 13), as molecular tags to isolate genetic regions, isolate genes, map genes, and determine gene function (pg. 14), and identifying tissues (pg. 14).<sup>1</sup> The specification states that the nucleic acid ESTs of the present invention can enable the acquisition of molecular markers, which can be used in breeding schemes, genetic and molecular mapping and cloning of agronomically significant genes (pg. 31).

In the examiner's opinion "[t]hese are non-specific uses that are applicable to nucleic acids in general and not particular or specific to the nucleic acids being claimed." Answer, page 6. For example, the examiner finds (Answer, page 10), "determining whether the claimed nucleic acids have or do not have a polymorphism would require determining whether there was a polymorphism within such a sequence and then determining how to use this information in a patentably meaningful way."

---

<sup>1</sup> During the Oral Hearing, appellants' representative confirmed that the administrative file contained no evidence that the claimed ESTs were capable of detecting a polymorphism that correlated with any particular trait.



In presenting their case on appeal, appellants focus on use of the claimed nucleic acid molecules to identify the presence or absence of a polymorphism, and their use as probes or as a source for primers. See e.g., Brief, pages 6-12. According to appellants (Brief, page 3), "they have disclosed nucleic acid molecules which, in their current form, provide at least one specific benefit to the public, for example the ability to identify the presence or absence of a polymorphism in a population of maize plants." Furthermore, appellants assert (Brief, page 8), "[t]he specification discloses that the claimed nucleic acid molecules can be used to isolate nucleic acid molecules of other plants and organisms...."

#### CLAIM CONSTRUCTION

As set forth above, claim 1 on appeal is drawn to a substantially purified nucleic acid molecule that encodes a maize protein or fragment thereof comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1 through SEQ ID NO:5. According to appellants' specification (page 15, lines 19-25), the term "substantially purified"

refers to a molecule separated from substantially all other molecules normally associated with it in its native state. More preferably a substantially purified molecule is the predominant species present in a preparation. A substantially purified molecule may be greater than 60% free, preferably 75% free, more preferably 90% free, and most preferably 95% free from the other molecules (exclusive of solvent) present in the natural mixture. The term "substantially purified" is not intended to encompass molecules present in their native state.

As we understand the claimed invention the use of the transitional term "comprising" does not allow for internal alterations (e.g. insertions or deletions) of

the nucleotide sequences set forth in SEQ ID NO: 1 through SEQ ID NO: 5, but instead only allows for the addition of nucleotides or other molecules at either end of the nucleotide sequences set forth in SEQ ID NO: 1 through SEQ ID NO: 5.<sup>2</sup> In this regard, we recognize, as does the examiner (Answer, page 14), the claim as written encompasses, inter alia, genes, full open reading frames, fusion constructs, and cDNAs.

Accordingly, for the purposes of our review, we interpret the claimed invention as drawn to a nucleic acid molecule, separated from substantially all other molecules normally associated with it in its native state, selected from the group consisting of the nucleic acid molecule defined by the 429 nucleotide sequence set forth in SEQ ID NO: 1, the 413 nucleotide sequence set forth in SEQ ID NO: 2, the 365 nucleotide sequence set forth in SEQ ID NO: 3, the 414 nucleotide sequence set forth in SEQ ID NO: 4, and the 333 nucleotide sequence set forth in SEQ ID NO: 5, with or without any preceding or trailing nucleotides, or other molecules.

## DISCUSSION

### Utility

The starting point for determining whether a nucleic acid molecule selected from the group consisting of SEQ ID NO: 1 through SEQ ID NO: 5

---

<sup>2</sup> This interpretation of the claimed invention was confirmed by appellants' representative during the Oral Hearing.

possesses utility under 35 U.S.C. § 101 is Brenner v. Manson, 383 U.S. 519, 148 USPQ 689 (1966). As set forth in Brenner, at 534-35, 148 USPQ at 695<sup>3</sup>,

the basic quid pro quo contemplated by the Constitution and the Congress for granting a patent monopoly is the benefit derived by the public from an invention with substantial utility. Unless and until [an invention] is refined and developed to this point--where specific benefit exists in currently available form--there is insufficient justification for permitting an applicant to engross what may prove to be a broad field.

In considering the issues presented in this appeal, special attention must be paid to the Brenner court's statement that a patent should issue only when an invention possesses "substantial utility," i.e., "where a specific benefit exists in currently available form." Whether a claimed invention is useful under 35 U.S.C. § 101 is a question of fact. Cross v. Iizuka, 753 F.2d 1040, 1044 n.7, 224 USPQ 739, 742 n.7 (Fed. Cir. 1985).

At issue in Brenner was a claim to "a chemical process which yields an already known product whose utility—other than as a possible object of scientific inquiry—ha[d] not yet been evidenced." Id. at 529, 148 USPQ at 693. The Patent Office had rejected the claimed process for lack of utility, on the basis that the product produced by the claimed process had not been shown to be useful. See id. at 521-22, 148 USPQ at 690. On appeal, the Court of Customs and Patent Appeals reversed, on the basis that "where a claimed process produces a

---

<sup>3</sup> In discussing the issue of utility under 35 U.S.C. § 101, the Federal Circuit and the Court of Customs and Patent Appeals since Brenner, have used the phrases "substantial utility" and "practical utility" interchangeably. See e.g., Fujikawa v. Wattanasin, 93 F.3d 1559, 1963-1964, 39 USPQ2d 1895, 1898-1899 (Fed. Cir. 1996) ("It is well established that a patent may not be granted to an invention unless substantial or practical utility for the invention has been discovered and disclosed.").

known product it is not necessary to show utility for the product." Id. at 522, 148 USPQ at 691.

The Brenner Court noted that although § 101 requires that an invention be "useful," that "simple, everyday word can be pregnant with ambiguity when applied to the facts of life." Id. at 529, 148 USPQ at 693. Thus,

[i]t is not remarkable that differences arise as to how the test of usefulness is to be applied to chemical processes. Even if we knew precisely what Congress meant in 1790 when it devised the "new and useful" phraseology and in subsequent re-enactments of the test, we should have difficulty in applying it in the context of contemporary chemistry, where research is as comprehensive as man's grasp and where little or nothing is wholly beyond the pale of "utility"—if that word is given its broadest reach.

Id. at 530, 148 USPQ at 694.<sup>4</sup>

The Court, finding "no specific assistance in the legislative materials underlying § 101," based its analysis on "the general intent of Congress, the purposes of the patent system, and the implications of a decision one way or the other." Id. at 532, 148 USPQ at 695. The Court concluded that "[t]he basic quid pro quo contemplated by the Constitution and the Congress for granting a patent monopoly is the benefit derived by the public from an invention with substantial utility. Unless and until a process is refined and developed to this point—where specific benefit exists in currently available form—there is insufficient justification for permitting an applicant to engross what may prove to be a broad field." Id. at 534-35, 148 USPQ at 695.

---

<sup>4</sup> The invention at issue in Brenner was a process, but the Court expressly noted that its holding "would apply equally to the patenting of the product produced by the process." Id. at 535, 148 USPQ at 695-96.

The Court considered and rejected the applicant's argument that attenuating the requirement of utility "would encourage inventors of new processes to publicize the event for the benefit of the entire scientific community, thus widening the search for uses and increasing the fund of scientific knowledge." The Court noted that, while there is value to encouraging disclosure, "a more compelling consideration is that a process patent in the chemical field, which has not been developed and pointed to the degree of specific utility, creates a monopoly of knowledge which should be granted only if clearly commanded by the statute. Until the process claim has been reduced to production of a product shown to be useful, the metes and bounds of that monopoly are not capable of precise delineation. It may engross a vast, unknown, and perhaps unknowable area. Such a patent may confer power to block off whole areas of scientific development." Id. at 534, 148 USPQ at 695.

The Court took pains to note that it did not "mean to disparage the importance of contributions to the fund of scientific information short of the invention of something 'useful,'" and that it was not "blind to the prospect that what now seems without 'use' may tomorrow command the grateful attention of the public." Id. at 535-36, 148 USPQ at 696. Those considerations did not sway the Court, however, because "a patent is not a hunting license. It is not a reward for the search, but compensation for its successful conclusion." Id.

Subsequent decisions of the CCPA and the Court of Appeals for the Federal Circuit have added further layers of judicial gloss to the meaning of

§ 101's utility requirement. The first opinion of the CCPA applying Brenner was In re Kirk, 376 F.2d 936, 153 USPQ 48 (CCPA 1967). The invention claimed in Kirk was a set of steroid derivatives said to have valuable biological properties and to be of value "in the furtherance of steroidal research and in the application of steroidal materials to veterinary or medical practice." Id. at 938, 153 USPQ at 50. The claims had been rejected for lack of utility. In response, the applicants submitted an affidavit which purportedly "show[ed] that one skilled in the art would be able to determine the biological uses of the claimed compounds by routine tests." Id. at 939, 153 USPQ at 51.

The court held that "nebulous expressions [like] 'biological activity' or 'biological properties'" did not adequately convey how to use the claimed compounds. Id. at 941, 153 USPQ at 52. Nor did the applicants' affidavit help their case: "the sum and substance of the affidavit appear[ed] to be that one of ordinary skill in the art would know 'how to use' the compounds to find out in the first instance whether the compounds are—or are not—in fact useful or possess useful properties, and to ascertain what those properties are." Id. at 942, 153 USPQ at 53.

The Kirk court held that an earlier CCPA decision, holding that a chemical compound meets the requirements of § 101 if it is useful to chemists doing research on steroids, had effectively been overruled by Brenner. "There can be no doubt that the insubstantial, superficial nature of vague, general disclosures or arguments of 'useful in research' or 'useful as building blocks of value to the

researcher' was recognized, and clearly rejected, by the Supreme Court" in Brenner. See Kirk, 376 F.2d at 945, 153 USPQ at 55.

More recently, in In re Ziegler, 992 F.2d 1197, 26 USPQ2d 1600 (Fed. Cir. 1993), the Federal Circuit considered the degree of specificity required to show utility for a claim to polypropylene. The U.S. application on appeal in Ziegler claimed priority to a German application filed in 1954. "In the German application, Ziegler disclosed only that solid granules of polypropylene could be pressed into a flexible film with a characteristic infrared spectrum and that the polypropylene was 'plastic-like.'" Id. at 1203, 26 USPQ2d at 1605. "Ziegler did not assert any practical use for the polypropylene or its film, and Ziegler did not disclose any characteristics of the polypropylene or its film that demonstrated its utility." Id. The court held that the German application did not satisfy the requirements of § 101 and therefore could not be relied on to overcome a rejection based on an intervening reference. Id. "[At] best, Ziegler was on the way to discovering a practical utility for polypropylene at the time of the filing of the German application; but in that application Ziegler had not yet gotten there." Id.

On the other hand, the CCPA reversed a rejection for lack of utility in In re Jolles, 628 F.2d 1322, 206 USPQ 885 (CCPA 1980). The applicant in Jolles claimed pharmaceutical compositions that were disclosed to be useful in treating acute myeloblastic leukemia. See id. at 1323, 206 USPQ at 886. The active ingredients in the compositions were closely related to daunorubicin and doxorubicin, both of which were "well recognized in the art as valuable for use in

cancer chemotherapy." Id., 206 USPQ at 887. The applicant also submitted declaratory evidence showing that eight of the claimed compositions were effective in treating tumors in a mouse model, and one was effective in treating humans. See id. at 1323-24, 206 USPQ at 887-88. The court noted that the data derived from the mouse model were "relevant to the treatment of humans and [were] not to be disregarded," id. at 1327, 206 USPQ at 890, and held that the evidence was sufficient to support the asserted therapeutic utility. See id. at 1327-28, 206 USPQ at 891.

The Federal Circuit held in Cross v. Iizuka, 753 F.2d 1040, 224 USPQ 739 (Fed. Cir. 1985), that in vivo testing (as in Jolles) was not necessarily required to show utility in the pharmaceutical context. The Cross court stated that "[it] is axiomatic that an invention cannot be considered 'useful,' in the sense that a patent can be granted on it, unless substantial or practical utility for the invention has been discovered and disclosed where such utility would not be obvious." Id. at 1044, 224 USPQ at 742 (citing Brenner v. Manson). The court "perceive[d] no insurmountable difficulty, under appropriate circumstances, in finding that the first link in the screening chain, in vitro testing, may establish a practical utility for the compound in question." Id. at 1051, 224 USPQ at 748. Successful in vitro testing could provide an immediate benefit to the public, by "marshall[ing] resources and direct[ing] the expenditure of effort to further in vivo testing of the most potent compounds ..., analogous to the benefit provided by the showing of an in vivo utility." Id. On the facts of that case – successful in vitro testing supplemented by similar in vitro and in vivo activities of structurally similar



compounds – the court held that in vitro activity was sufficient to meet the requirements of § 101. See id.

The Federal Circuit confirmed in In re Brana, 51 F.3d 1560, 34 USPQ2d 1436 (Fed. Cir. 1995), that human testing is not necessary to establish utility for a method of treatment. The invention claimed in Brana was a group of compounds disclosed to have antitumor activity. See id. at 1562, 34 USPQ2d at 1437-38. The specification disclosed that the claimed compounds had higher antitumor activity than related compounds known to have antitumor activity, and the applicants provided declaratory evidence of in vivo activity against tumors in a mouse model. See id., 34 USPQ2d at 1438. The court held that these data were sufficient to satisfy § 101; usefulness in patent law does not require that the invention be ready to be administered to humans. See id. at 1567, 34 USPQ2d at 1442.

Several lessons can be drawn from Brenner and its progeny. First, § 101's requirement that an invention be "useful" is not to be given its broadest reach, such that little or nothing of a chemical nature would be found to lack utility. See Brenner, 383 U.S. at 530, 148 USPQ at 694. Thus, not every "use" that can be asserted will be sufficient to satisfy § 101. For example, the steroid compound at issue in Brenner was useful as a possible object of scientific inquiry, and the polypropylene claimed in Ziegler was useful for pressing into a flexible film, yet both lacked sufficient utility to satisfy § 101. See Brenner, 383 U.S. at 529, 148 USPQ at 696; Ziegler, 992 F.2d at 1203, 26 USPQ2d at 1605.

Rather than setting a de minimis standard, § 101 requires a utility that is "substantial", i.e., one that provides a specific benefit in currently available form. Brenner, 383 U.S. at 534-35, 148 USPQ at 695. This standard has been found to be met by pharmaceutical compositions shown to be useful in mouse models and in humans for treating acute myeloblastic leukemia (Jolles, 628 F.2d at 1327-28, 206 USPQ at 891); by evidence showing successful in vitro testing supplemented by similar in vitro and in vivo activities of structurally similar compounds (Cross, 753 F.2d at 1051, 224 USPQ at 748); and by evidence showing in vivo antitumor activity in mice, combined with a disclosure that the claimed compounds had higher antitumor activity than a related compound known to have antitumor activity (Brana, 51 F.3d at 1567, 34 USPQ2d at 1442).

By contrast, Brenner's standard has been interpreted to mean that "vague, general disclosures or arguments of 'useful in research' or 'useful as building blocks of value to the researcher'" would not satisfy § 101. See Kirk, 376 F.2d at 945, 153 USPQ at 55 (interpreting Brenner). Likewise, a disclosure of a "plastic-like" polypropylene capable of being pressed into a flexible film was held to show that the applicant was "at best ... on the way to discovering a practical utility for polypropylene at the time of the filing," but not yet there. Ziegler, at 1203, 26 USPQ2d at 1605.

With these principles in mind we turn to the issues at hand. Of the many utilities asserted in the specification, two have received the most attention in the briefing in this appeal, i.e., identification and detection of polymorphisms and use

as probes or as a source for primers. We shall focus on these asserted utilities first and then address the other arguments set forth in the briefing.

a. Polymorphisms

This utility is discussed at pages 35-42 of the specification in terms of what polymorphisms are and how one would go about determining the existence of a polymorphism. The discussion in this portion of the specification, however, is not specific to the nucleotide molecules depicted in SEQ ID NO: 1 through SEQ ID NO: 5. To the contrary, according to appellants' specification (page 35, lines 25-26), "one or more of the [32,236] EST nucleic acid molecules (or a sub-fragment thereof) may be employed as a marker nucleic acid molecule to identify ... polymorphism(s)." The specification does not explain why any of the 32,236 nucleotide molecules disclosed in the specification, or more specifically the five nucleotide molecules depicted in SEQ ID NO: 1 through SEQ ID NO: 5, would in fact be useful in detecting polymorphisms.

Rather, appellants argue (Brief, page 7), "the claimed nucleic acid molecules have utility even if the absence of a particular polymorphism is detected. Indeed, the absence of a polymorphism usually demonstrates that the two (or more) populations being compared share a common genetic heritage." In other words, appellants' position is that an EST by definition possesses patentable utility because it can be used by itself in determining whether populations share a common genetic heritage. While that may be a "utility," we do not find that it is a substantial utility.

Without knowing any further information in regard to the gene represented by an EST, as here, detection of the presence or absence of a polymorphism provides the barest information in regard to genetic heritage. As the examiner explains (Answer, bridging paragraph, pages 10-11):

Polymorphisms are natural variations within sequences which themselves may not have any meaningful use. Therefore, determining whether the claimed nucleic acids [(or nucleic acids detected by the claimed nucleic acids)] have or do not have a polymorphism would require determining whether there was a polymorphism within such a sequence and then determining how to use this information in a patentably meaningful way. The [a]ppellant also argues, "many of these uses are directly analogous to a microscope". This argument has been reviewed but is not convincing because the microscope provides information to the scientist which is automatically useful. For example, the microscope may be used for identification and differentiation between gram-positive and gram-negative bacteria. The differentiation of bacteria facilitates in the administration of proper antibiotics. For example, if the microscope is used to determine whether Staph is present or whether Strep is present provides valuable information to the scientist and/or doctor for treating patients. The instant invention, however, provides no information to this extent. If the scientist determines that SEQ ID NO: 1 is present, the scientist does not know how to use this information. Thus, the identification of SEQ ID NO: 1 is not a substantial utility.

In contrast, at the other end of the "utility spectrum" would be information gleaned from detecting the presence or absence of a polymorphism when it is known what effect the gene from which the EST is derived has in the development and/or phenotype of the plant. Somewhere between having no knowledge (the present circumstances) and having complete knowledge of the gene and its role in the plant's development and/or phenotype lies the line between "utility" and "substantial utility." We need not draw the line or further

define it in this case because the facts in this case represent the lowest end of the spectrum, i.e., an insubstantial use.

b. Probes or source of primers

Appellants argue that the "specification discloses that the claimed nucleic acid molecules can be used to isolate nucleic acid molecules of other plants and organisms...." Appeal Brief, page 8. While that may be true, it begs the question of what substantial use such nucleic acid molecules would have? Again, the present specification does not attribute any property in terms of plant trait, or phenotype to any of the nucleotide molecules set forth in SEQ ID NO: 1 through SEQ ID NO: 5. In the absence of such information, using the claimed molecules to isolate other molecules, which themselves lack substantial utility, does not represent a substantial utility.

Appellants also assert that the claimed nucleic acid molecules may be used in a "chromosome walk." Brief, pages 8-9. According to appellants (Brief, page 9),

The claimed nucleic acid molecules provide a particularly appropriate and demonstrably useful starting point for a walk to isolate a promoter that is active in leaves at the time of anthesis. Isolation of such a promoter would be desirable and particularly useful because it allows expression of proteins at that important developmental state, including proteins that provide disease resistance. Because the claimed nucleic acid molecules were isolated from leaves, they provide an appropriate starting point for isolating a promoter active in leaves. A random nucleic acid molecule does not provide an equally good starting point to isolate such a promoter.

As we understand this argument, the claimed ESTs may be useful in searching for promoters that are only active in leaves at the time of anthesis. The

specification, however, fails to demonstrate that any of the nucleic acid molecules set forth in SEQ ID NO: 1 through SEQ ID NO: 5 would be useful in obtaining a successful result from such a search. As set forth at page 34, lines 14-19 of appellants' specification,

The [32,236] nucleic acid molecules of the present invention may be used to isolate promoters of tissue enhanced[,] tissue specific, cell-specific, cell -type, developmentally or environmentally regulated expression profiles. Isolation and functional analysis of the 5' flanking promoter sequences of these genes from genomic libraries, for example, using genomic screening methods and PCR techniques would result in the isolation of useful promoters and transcriptional regulatory elements.

The specification does not provide any expectation of successfully using any of the 32,236 nucleic acid molecules disclosed in the specification, or more specifically the five nucleic acid molecules depicted in SEQ ID NO: 1 through SEQ ID NO: 5, to isolate promoters of tissue enhanced, tissue specific, cell-specific, cell-type, developmentally or environmentally regulated expression profiles.

Furthermore, notwithstanding appellants' assertion (Brief, page 9), there is no evidence on this record that any of the nucleic acid molecules depicted in SEQ ID NO: 1 through SEQ ID NO: 5 are tissue or cell-type specific, or developmentally or environmentally regulated. In this regard, we note that the claimed nucleic acid molecules were isolated from the cDNA library LIB3115. Specification, page 80, lines 5-6. There is no evidence on this record that LIB3115 is a subtractive cDNA library, wherein nucleic acid molecules from other maize tissue, or from other developmental stages, was subtracted (removed)

from the library. Compare, for example, the subtractive cDNA library LIB3153 which is disclosed (specification, page 83, lines 17-19) to be "generated by subtracting driver cDNA, which is prepared from kernels harvested from 15 DAP [days after pollination] maize plants, from target cDNA, which is prepared from endosperms harvested from 5-8 day[s] after pollination (DAP) maize plants." In contrast to the claimed nucleic acid molecules, nucleic acid molecules SEQ ID NO: 24,931 through SEQ ID NO: 25,680 are from the subtractive cDNA library LIB3153.

In our opinion, the claimed nucleic acid molecules having the sequences identified as SEQ ID NO: 1 through SEQ ID NO: 5, represent five randomly selected nucleic acid molecules isolated from pooled leaf tissue at the time of anthesis. Notwithstanding appellants' emphasis on "anthesis," for the foregoing reasons, we find no evidence on this record that any of appellants' five randomly selected nucleic acid molecules are expressed only at the time of "anthesis." Accordingly, despite appellants' assertion to the contrary, there is no reasonable expectation that any of the claimed nucleic acid molecules would be capable of isolating a promoter that was only active in leaves at the time of anthesis. As appellants recognize (Brief, page 9), "[a] random nucleic acid molecule does not provide an equally good starting point to isolate such a promoter" compared to a nucleic acid molecule that is known to be specifically associated with this stage of plant development.

We recognize appellants' argument (Brief, bridging sentence, pages 9-10), "[a]n invention may be 'less effective than existing devices but nevertheless

meet the statutory criteria for patentability.' Custom Accessories, Inc. v. Jeffrey-Allan Indus., 807 F.2d 955, 960 n.12, 1 U.S.P.Q.2d 1196, 1199 n.12 (Fed. Cir. 1986)." While we agree with appellants' statement, we fail to see how it applies to appellants' claimed invention, wherein there is no evidence or expectation that the claimed nucleic acid molecules would be "effective" at all. In this regard, we remind appellants that an invention does not have utility sufficient to satisfy § 101 until it is "refined and developed" to the point of providing a specific benefit in currently available form. See, e.g., Brenner, 383 U.S. at 534, 148 USPQ at 695.

An invention certainly can have a utility that is shared by other compounds or compositions. Take, for example, an application that claims ibuprofen and discloses that it is useful as an analgesic. No one would argue that a claim to ibuprofen lacks utility simply because aspirin and acetaminophen are also useful as analgesics. On the other hand, not every utility will satisfy § 101, even if the utility is shared by a class of inventions. Assume that the above-described application did not disclose that ibuprofen was an analgesic but only disclosed that it is useful because it can be used to fill a jar, which would then be useful as a paperweight. There would be little doubt that this disclosed utility would not satisfy § 101, even though the utility is shared by a large class of inventions, viz., those whose physical embodiments have mass. So while a utility need not be unique to a claimed invention, it must nonetheless be specific, and in currently available form, in order to satisfy § 101.



c. Other Arguments

Appellants argue that the specification "discloses additional utilities for the claimed nucleic acid molecules including introduction of the claimed nucleic acid molecules into a plant or plant cell (either as sense or antisense inhibitors), which can then be used to screen for compounds such as a herbicide." Brief, page 6. Specifically, appellants argue (id.) that "a compound can be provided to both an antisense plant and a control plant (no antisense) and the effect of the compound on the plant can be monitored." Appellants analogize this proposed procedure to a "cell-based assay" which appellants assert to have a "legally sufficient utility." Id.

Suffice it to say that an otherwise uncharacterized nucleic acid molecule is being claimed in this application, not an assay. The portion of the specification cited in support of this argument (page 73, line 17 through page 74, line 17) indicates that the nucleic acid molecule must be introduced into a plant cell and transcribed using an appropriate promoter to result in the suppression of an endogenous protein. The specification does not indicate that such a method is feasible when the nucleic acid to be used is uncharacterized<sup>5</sup> as here. Such a use does not provide a specific or substantial benefit in currently available form.

Appellants also argue that the claimed nucleic acids are useful to measure the level of mRNA in a sample through use of microarray technology

---

<sup>5</sup> To emphasize the uncharacterized nature of appellants' invention we note the examiner's finding (Answer, page 17) that translating SEQ ID NO: 5 in all 6 possible reading frames reveals that the sequence contains numerous stop codons which would terminate the translation of a protein, or protein fragment, encoded thereby.

and use as molecular markers. Brief, page 6. In regard to microarrays, appellants argue (*id.* fn. 3) that it is "standard practice" to screen populations of nucleic acids with EST sequences without characterizing each and every target mRNA. We find that the asserted utility of the claimed nucleic acid—as one component of an assay for monitoring gene expression—does not satisfy the utility requirement of § 101. Such a use does not provide a specific benefit in currently available form. We accept, for argument's sake, that a person skilled in the art could use the claimed nucleic acid, in combination with other nucleic acids, to monitor changes in expression of the gene that encompasses the nucleic acid depicted in e.g., SEQ ID NO: 1. However, the specification provides no guidance that would allow a skilled artisan to use data relating to expression of such a gene in any practical way. The specification simply provides no guidance regarding what the SEQ ID NO: 1-specific information derived from a gene expression experiment would mean. As the examiner points out (Answer, page 9), "the instant claimed nucleic acids appear to require further experimentation on the material itself to determine the function and properties of the claimed nucleic acids."

To highlight the examiner's assertion, suppose, for example, that a researcher found that SEQ ID NO: 1 expression was increased when a cell was treated with a particular agent. The specification provides no basis on which a skilled worker would be able to determine whether that result is meaningful. Maybe the meaning in a change in SEQ ID NO: 1 expression would depend on other factors, but again the specification provides no hint as to what other factors

might be important. Would it depend on what agent is used, what cell type is used, the behavior of other genes (if so, which genes and what behavior is significant), the degree of increase? The specification simply provides no guidance as to how to interpret the results that might be seen using SEQ ID NO: 1 in a gene expression assay.

In effect, appellants' position is that the claimed nucleic acids are useful because those of skill in the art could experiment with them and figure out for themselves what any observed experimental results might mean. We do not agree that such a disclosure provides a "specific benefit in currently available form." Rather, the present case seems analogous to Brenner. In Brenner, the applicant claimed a method of making a compound but disclosed no utility for the compound. 383 U.S. at 529, 148 USPQ at 693. The Court held that a process lacks utility if it produces a product that lacks utility. Id. at 534, 148 USPQ at 695. Here, appellants claim a product asserted to be useful in a method of generating gene-expression data, but the specification does not disclose how to interpret those data. Just as the process claimed in Brenner lacked utility because the specification did not disclose how to use the end-product, the products claimed here lack utility, because even if used in gene expression assays, the specification does not disclose how to use SEQ ID NO: 1-specific gene expression data.

Assuming arguendo, that a generic gene expression assay—one based on monitoring expression of thousands of uncharacterized nucleic acids would provide a useful tool for, e.g., drug discovery, it does not follow that each one of

the nucleic acids represented in the assay individually has patentable utility.

Although each nucleic acid in the assay contributes to the data generated by the assay overall, the contribution of a single nucleic acid—its data point—is only a tiny contribution to the overall picture. The Brenner Court held that § 101 sets more than a de minimis standard for utility. Therefore, the patentable utility of a gene expression assay, for example, does not necessarily mean that each tiny component of the assay also has patentable utility. A patentable utility divided by a thousand does not necessarily equal a thousand patentable utilities. Each claimed invention must be shown to meet § 101's utility requirement in order to be patentable; it must provide a specific benefit in currently available form.

Providing a single data point among thousands or millions, even if the thousands or millions of data points collectively are useful, does not meet this standard.

The Supreme Court noted that the patent system contemplates a basic quid pro quo: in exchange for the legal right to exclude others from his invention for a period of time, an inventor discloses his invention to the public. See Brenner, 383 U.S. at 534, 148 USPQ at 695. The Brenner Court held that the grant of patent rights to an applicant is justified only by disclosure of an invention with substantial utility – a specific benefit in currently available form. Until the invention has been refined and developed to this point, the Court held, the applicant has not met his side of the bargain, and has not provided a disclosure sufficient to justify a grant of the right to exclude others. See id.

We reach the same conclusion in regard to appellants' assertion that the nucleic acid molecules depicted in SEQ ID NO: 1 through SEQ ID NO: 5 are

useful as a molecular marker or probe. It is not seen that the one data point which may be provided by using the uncharacterized nucleic acid molecule of SEQ ID NO: 1 as a molecular marker or probe represents a substantial use.

Appellants argue that ESTs have real world value as seen from the "growth of a multi-million dollar industry in the United States premised on the usefulness of ESTs." Brief, page 11. Since appellants fail to provide any suggestion on which use of ESTs this industry is premised on, we can only assume that appellants are referring to the potential usefulness of EST databases, clone sets or microarrays. Suffice it to say, the claims on appeal are not directed to EST databases, clone sets and/or microarrays. Again, it is not seen that the one data point which may be provided by using the uncharacterized nucleic acid molecules of SEQ ID NO: 1 through SEQ ID NO: 5 in such devices represents a substantial use.

For the foregoing reasons we affirm the rejection of claim 1 under 35 U.S.C. § 101.

#### Enablement

According to the examiner (Answer, page 13, emphasis removed), "since the claimed invention is not supported by either a specific, substantial asserted utility or a well established utility for the reasons set forth [in support of the rejection under 35 U.S.C. § 101] one skilled in the art clearly would not know how to use the claimed invention." This rejection is simply a corollary of the finding of lack of utility. Appellants assert (Brief, page 12), this rejection should be reversed for the same reasons set forth in their arguments regarding the

rejection under 35 U.S.C. § 101. Thus, our conclusion with respect to the § 101 issue will also apply to this aspect of the § 112 (enablement) issue. On this basis we affirm the rejection of claim 1 under the enablement provision of 35 U.S.C. § 112, first paragraph.

Written description

This rejection stands on a different footing. As we understand the examiner's argument the use of the transitional phrase "comprising" in appellants' claimed invention results in appellants claiming a large genus of nucleic acid molecules which are not adequately described by SEQ ID NO: 1 through SEQ ID NO: 5. Answer, pages 13-16. Apparently the examiner is of the opinion that the claimed invention should be limited to nucleic acid molecules as set forth in SEQ ID NO: 1 through SEQ ID NO: 5. In response appellants argue (Brief, page 14, original footnote omitted),

Applicants have provided the nucleotide sequences required by the claims, i.e., SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5, and have thus established possession of the claimed invention. The fact that the claims at issue are intended to cover molecules that include the recited sequences joined with additional sequences<sup>6</sup> does not mean that [a]pplicants were any less in possession of the claimed nucleic acid molecules.

As discussed supra, as we understand the claimed invention, the use of the transitional term "comprising" does not allow for internal alterations (e.g. insertions or deletions) of the nucleotide sequences set forth in SEQ ID NO: 1

---

<sup>6</sup> By way of examples appellants explain (Brief, bridging paragraph, pages 14-15) that the specification discloses, inter alia, the claimed nucleic acid molecules joined together with vectors, and other nucleic acids (e.g. fusion nucleic acid molecules) and detectable labels.

through SEQ ID NO: 5, but instead only allows for the addition of nucleotides or other molecules at either end of the nucleotide sequences set forth in SEQ ID NO: 1 through SEQ ID NO: 5. We agree with appellants that they have provided an adequate written description of nucleic acid molecules with the sequences set forth in SEQ ID NO: 1 through SEQ ID NO: 5. That the claimed nucleic acid molecules may have other molecules attached to either, or both of their 5' or 3' ends does not diminish appellants' adequate written description of the nucleic acids molecules with the sequences set forth in SEQ ID NO: 1 through SEQ ID NO: 5 as claimed.

Accordingly, we reverse the rejection of claim 1 under the written description provision of 35 U.S.C. § 112, first paragraph.

No time period for taking any subsequent action in connection with this appeal may be extended under 37 CFR § 1.136(a).


AFFIRMED

  
William F. Smith

Administrative Patent Judge



Donald E. Adams  
Administrative Patent Judge



Eric Grimes  
Administrative Patent Judge

)  
)  
)  
) BOARD OF PATENT  
)  
) APPEALS AND  
) INTERFERENCES  
)  
)  
)

Appeal No. 2002-2046  
Application No. 09/619,643

Page 27

Lawrence M Lavin Jr Esq  
Monsanto Company  
Patent Department E2NA  
800 N Lindbergh Boulevard  
St. Louis MO 63167